|
1
|
Zhou K, Zhang SS, Yan Y and Zhao S:
Overexpression of transient receptor potential vanilloid 2 is
associated with poor prognosis in patients with esophageal squamous
cell carcinoma. Med Oncol. 31:172014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Napier KJ, Scheerer M and Misra S:
Esophageal cancer: A review of epidemiology, pathogenesis, staging
workup and treatment modalities. World J Gastrointest Oncol.
6:112–120. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Toh Y, Egashira A and Yamamoto M:
Epigenetic alterations and their clinical implications in
esophageal squamous cell carcinoma. Gen Thorac Cardiovasc Surg.
61:262–269. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Song Y, Li L, Ou Y, Gao Z, Li E, Li X,
Zhang W, Wang J, Xu L, Zhou Y, et al: Identification of genomic
alterations in oesophageal squamous cell cancer. Nature. 509:91–95.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin S and Gregory RI: MicroRNA biogenesis
pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gu J, Wang Y and Wu X: MicroRNA in the
pathogenesis and prognosis of esophageal cancer. Curr Pharm Des.
19:1292–1300. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Feber A, Xi L, Luketich JD, Pennathur A,
Landreneau RJ, Wu M, Swanson SJ, Godfrey TE and Litle VR: MicroRNA
expression profiles of esophageal cancer. J Thorac Cardiovasc Surg.
135:255–260. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
He B, Yin B, Wang B, Xia Z, Chen C and
Tang J: MicroRNAs in esophageal cancer (Review). Mol Med Rep.
6:459–465. 2012.PubMed/NCBI
|
|
11
|
Li P, Mao WM, Zheng ZG, Dong ZM and Ling
ZQ: Down-regulation of PTEN expression modulated by dysregulated
miR-21 contributes to the progression of esophageal cancer. Dig Dis
Sci. 58:3483–3493. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sugimura K, Miyata H, Tanaka K, Hamano R,
Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Mori
M and Doki Y: Let-7 expression is a significant determinant of
response to chemotherapy through the regulation of IL-6/STAT3
pathway in esophageal squamous cell carcinoma. Clin Cancer Res.
18:5144–5153. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin RJ, Xiao DW, Liao LD, Chen T, Xie ZF,
Huang WZ, Wang WS, Jiang TF, Wu BL, Li EM and Xu LY: MiR-142-3p as
a potential prognostic biomarker for esophageal squamous cell
carcinoma. J Surg Oncol. 105:175–182. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kano M, Seki N, Kikkawa N, Fujimura L,
Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M and
Matsubara H: miR-145, miR-133a and miR-133b: Tumor-suppressive
miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J
Cancer. 127:2804–2814. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Clough E and Barrett T: The gene
expression omnibus database. Methods Mol Biol. 1418:93–110. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qian Y, Yuan J, Hu H, Yang Q, Li J, Zhang
S, Jiang B, Shao C and Gong Y: The CUL4B/AKT/β-catenin axis
restricts the accumulation of myeloid-derived suppressor cells to
prohibit the establishment of a tumor-permissive microenvironment.
Cancer Res. 75:5070–5083. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Williams AH, Liu N, van Rooij E and Olson
EN: MicroRNA control of muscle development and disease. Curr Opin
Cell Biol. 21:461–469. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kirby TJ and McCarthy JJ: MicroRNAs in
skeletal muscle biology and exercise adaptation. Free Radic Biol
Med. 64:95–105. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao Y, Huang J, Zhang L, Qu Y, Li J, Yu
B, Yan M, Yu Y, Liu B and Zhu Z: MiR-133b is frequently decreased
in gastric cancer and its overexpression reduces the metastatic
potential of gastric cancer cells. BMC Cancer. 14:342014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao H, Li M, Li L, Yang X, Lan G and
Zhang Y: MiR-133b is down-regulated in human osteosarcoma and
inhibits osteosarcoma cells proliferation, migration and invasion,
and promotes apoptosis. PLoS One. 8:e835712013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hu G, Chen D, Li X, Yang K, Wang H and Wu
W: miR-133b regulates the MET proto-oncogene and inhibits the
growth of colorectal cancer cells in vitro and in vivo. Cancer Biol
Ther. 10:190–197. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Higa LA, Wu M, Ye T, Kobayashi R, Sun H
and Zhang H: CUL4-DDB1 ubiquitin ligase interacts with multiple
WD40-repeat proteins and regulates histone methylation. Nat Cell
Biol. 8:1277–1283. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kerzendorfer C, Hart L, Colnaghi R,
Carpenter G, Alcantara D, Outwin E, Carr AM and O'Driscoll M:
CUL4B-deficiency in humans: Understanding the clinical consequences
of impaired Cullin 4-RING E3 ubiquitin ligase function. Mech Ageing
Dev. 132:366–373. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dong J, Wang XQ, Yao JJ, Li G and Li XG:
Decreased CUL4B expression inhibits malignant proliferation of
glioma in vitro and in vivo. Eur Rev Med Pharmacol Sci.
19:1013–1021. 2015.PubMed/NCBI
|
|
27
|
Chen Z, Shen BL, Fu QG, Wang F, Tang YX,
Hou CL and Chen L: CUL4B promotes proliferation and inhibits
apoptosis of human osteosarcoma cells. Oncol Rep. 32:2047–2053.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jiang T, Tang HM, Wu ZH, Chen J, Lu S,
Zhou CZ, Yan DW and Peng ZH: Cullin 4B is a novel prognostic marker
that correlates with colon cancer progression and pathogenesis. Med
Oncol. 30:5342013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jia S, Kobayashi R and Grewal SI:
Ubiquitin ligase component Cul4 associates with Clr4 histone
methyltransferase to assemble heterochromatin. Nat Cell Biol.
7:1007–1013. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dumbliauskas E, Lechner E, Jaciubek M,
Berr A, Pazhouhandeh M, Alioua M, Cognat V, Brukhin V, Koncz C,
Grossniklaus U, et al: The Arabidopsis CUL4-DDB1 complex interacts
with MSI1 and is required to maintain MEDEA parental imprinting.
EMBO J. 30:731–743. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Higa LA, Yang X, Zheng J, Banks D, Wu M,
Ghosh P, Sun H and Zhang H: Involvement of CUL4 ubiquitin E3
ligases in regulating CDK inhibitors Dacapo/p27Kip1 and cyclin E
degradation. Cell Cycle. 5:71–77. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nishitani H, Shiomi Y, Iida H, Michishita
M, Takami T and Tsurimoto T: CDK inhibitor p21 is degraded by a
proliferating cell nuclear antigen-coupled Cul4-DDB1Cdt2 pathway
during S phase and after UV irradiation. J Biol Chem.
283:29045–29052. 2008. View Article : Google Scholar : PubMed/NCBI
|
